Skip to content

Based on AI emotional intervention comprehensive clinical application research of digital therapy system

Based on AI emotional intervention comprehensive clinical application research of digital therapy system

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101283
Enrollment
Unknown
Registered
2025-04-23
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive disorder

Interventions

Intervention group:Adaptive computerized cognitive training with multi-domain coordination was performed for 12 weeks and drug intervention for 16 weeks. The specific requirements of drug intervention
For people aged 60 and above, it is necessary to train daily, training time is 50-55 minutes.
Control group:Drug intervention was performed for 16 weeks. Antidepressant treatment included selective serotonin reuptake inhibitors and 5-HT and norepinephrine reuptake inhibitors, including fluoxet

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 14-80 years old; 2. Have a previously diagnosed depressive disorder; 3. Depression Anxiety and Stress Scale (DASS-21) Depression score: 10-20; 4. The patient has the chief complaint of cognitive decline or the performance of cognitive impairment (the basic cognitive ability test evaluates cognitive function, which is lower than the normal norm); 5. Primary school education or above, able to complete relevant assessment; 6. Patients voluntarily participate in the study and sign the informed consent;

Exclusion criteria

Exclusion criteria: 1) A history of substance abuse, drug use, or alcohol abuse as defined in the DSM-5 criteria within the year prior to enrollment; 2) electroconvulsive therapy within 6 months (including 6 months) before enrollment; 3) Have neurological diseases (including mental retardation, neurodegenerative diseases or severe acquired brain injury, such as stroke, brain tumor resection, traumatic brain injury, etc.); 4) Taking drugs that affect cognitive function (methylphenidate, tomoxetine, mofedanil, ginkgo extract, and huperzine A); 5) Diagnosis of a systemic disease that has the potential to impair cognitive function (type I diabetes, thyroid disease, kidney disease, liver disease, hematological malignancies, or ongoing cancer treatment); 6) Unable to complete the test and assessment due to problems such as vision, hearing, and severe physical impairment; 7) The condition is unstable (such as acute myocardial infarction, acute heart failure) or the patient is unwilling to cooperate; 8) Speech disorders, or episodes of mental disorders, and patients with a life expectancy of less than 12 months.

Design outcomes

Primary

MeasureTime frame
Primary Ability of Cognitive Test , PACT;

Secondary

MeasureTime frame
Depression Anxiety and Stress Scale,DASS-21;Patient Health Questionnaire-9,PHQ-9;Generalized Anxiety Disorder-7,GAD-7;Pittsburgh Sleep Quality Index,PSQI;Mini-Mental State Examination , MMSE;Montreal Cognitive Assessment , MOCA;

Countries

China

Contacts

Public ContactQinge Zhang

Beijing Anding Hospital, Capital Medical University

zqe81@126.com+86 10 5830 3007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026